logo

Catalyst Biosciences Inc. (CBIO)



Trade CBIO now with
  Date
  Headline
4/6/2020 8:23:07 AM Catalyst Biosciences Gets Guidance From FDA And EMA On A Pivotal Phase 3 Trial Design For MarzAA
2/7/2020 3:36:53 AM Catalyst Biosciences Presents Positive Data From Phase 2b Trial Of DalcA And MarzAA Programs At EAHAD Congress
1/17/2020 8:12:07 AM Catalyst Biosciences Adds Geoffrey Shiu Fei Ling And Sharon Tetlow To Board Of Directors
10/3/2019 8:09:30 AM Catalyst Biosciences Update On Enrollment In Phase 2b Study Of Dalcinonacog Alfa
7/8/2019 5:05:09 AM Catalyst Biosciences Meets Primary Endpoint In Phase 2 Trial Of Subcutaneous Marzeptacog Alfa (Activated)
2/6/2019 8:14:19 AM Catalyst Biosciences Announces Preclinical Proof-of-Concept Data Of Gene Therapy Candidate CB 2679d-GT For Hemophilia B
12/1/2018 12:34:34 PM Catalyst Biosciences Announces Updated Positive Interim Data From Phase 2/3 Study Of Marzeptacog Alfa (Activated)
11/1/2018 8:18:24 AM Catalyst Biosciences Q3 Loss Per Share $0.64 Vs Loss $1.34 Last Year
8/15/2018 8:08:47 AM Catalyst Biosciences Says Updated Positive Interim Data From Phase 2/3 Study Of SQ Prophylactic VIIa Variant MarzAA
8/2/2018 8:16:46 AM Catalyst Biosciences Q2 Loss Attributable To Stockholders $6.5 Mln Or $0.54/Shr Vs Loss $9.8 Mln Or $2.53/Shr Last Year
7/18/2018 7:00:44 AM Catalyst Biosciences Announces Positive Interim Data From Phase 2/3 Study Of Marzeptacog Alfa (Activated)
7/10/2018 8:08:37 AM Catalyst Biosciences Appoints Grant Blouse As VP Of Translational Research